Serious adverse events ( · adult patients with an implantable cardioverter defibrillator
It is very uncertain whether exercise changes serious adverse events ( compared with no exercise at longest available follow‐up (very low certainty).
1 finding from 1 review
Intervention not reported
There was no evidence of differences in the number of serious adverse events for any of the comparisons Quality of evidence = very low1,2,3. · people undergoing liver resection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
There was no evidence of differences in the proportion of participants experiencing serious adverse events (for any of the comparisons Quality of evidence = very low1,2,3. · people undergoing liver resection
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (surgery‐related adverse effects within 30 days) · people with a low platelet count
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing pancreaticoduodenectomy
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing distal pancreatectomy
1 finding from 1 review
Serious adverse events (transfusion‐related adverse effects within 24 hours of the transfusion) · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes serious adverse events (transfusion‐related adverse effects within… compared with alternative treatments (very low certainty).
1 finding from 1 review
Proportion of participants with 1 or more serious adverse events according to International Conference on Harmonisation Good Clinical Practice (ICH‐GCP) · adults admitted to the ICU
It is very uncertain whether higher changes proportion of participants with ≥ 1 serious adverse events according… compared with lower FiO2 or targets of arterial oxygenation (very low certainty).
1 finding from 1 review
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with shallow NMB (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (diabetes mellitus) · people undergoing pancreaticoduodenectomy
1 finding from 1 review
Intervention not reported
Death and serious adverse events, including falls · participants after stroke
1 finding from 1 review
Intervention not reported
Death and serious adverse events, including falls · participants after stroke
1 finding from 1 review
Any serious adverse event of treatment count of events · people with traumatic head injuries
Antiepileptic drugs showed no clear difference in any serious adverse event of treatment count of events compared with placebo or standard care (low certainty).
1 finding from 1 review
Mortality or serious adverse events requiring hospital admission · Adults or children at increased risk of bacterial endocarditis (pre-existing cardiac condition) undergoing an invasive dental procedure
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review